HIFU (high intensity focused ultrasound) as a non-invasive, outpatient treatment for prostate cancer received FDA approval in October of 2015. Since then, approximately 50 physicians throughout the United States have begun to offer this innovative procedure with the use of the Sonablate 500, the industry’s most advanced HIFU-delivering technology. But for many physicians and facilities who do not currently offer HIFU, the capital investment in this technology may be too great, coupled with the lack of experience or training to perform the procedure.
Now, there is a solution for those who wish to offer HIFU as a prostate cancer treatment in a sustainable economic framework – mobile, proctored HIFU services provided by International HIFU Centers, the global leader in HIFU for the treatment of prostate cancer with over 2,600 procedures performed.
“Urologists who currently perform HIFU have demonstrated successful clinical outcomes for their patients including reduced PSA levels and significantly diminished risks of side effects such as incontinence and impotence,” said Dr. George Suarez, founder of the International HIFU Centers and the medical director of the HIFU FDA clinical trials. “And, now, we want to make sure that all physicians and facilities have the opportunity to offer this innovative procedure to their patients that will increase patient safety, quality of life and overall clinical outcomes.”
International HIFU Centers (IHC) will provide on-site proctors, trainers and technicians who are specially trained and certified in the application of HIFU throughout the duration of the session. As well, they will oversee the management of all billing and collection of patient fees, including payment to the facility and/or physician at the time of service. In addition, IHC will transport and allow on-site use of the Sonablate 500 to perform the HIFU procedure.
The Sonablate technology has several unique software features, including use of MRI/US fusion to precisely target regions slated for ablation. In addition, Sonablate provides the feedback data required by the physician to assess how the prostate is responding to energy disposition, and the tools required to modify that energy to achieve complete ablation. These multiple and unique features all play a role in providing the accuracy, consistency, and safety required for the delivery of focused ultrasound energy to the prostate.
HIFU can be used as an alternative to chemotherapy, surgery, radiation and for post-radiation cancer recurrence, which occurs in about 50,000 men annually. HIFU is a self-pay procedure not currently covered by commercial insurances; however, the Centers for Medicaid and Medicare services has accepted a C-code which is applicable to procedures performed in hospital and ASC facilities under the Medicare Hospital Outpatient Prospective Payment System (OPPS).
For more information about HIFU mobile services, call 305-274-7144 or email [email protected]